PERRIGO Co plc
No SEC Form 4 filings for $PRGO in the last 30 days.
See all $PRGO insider activity →Elf Beauty (ELF) shares rose after Canaccord's sales tracker showed 11.6% year-over-year dollar sales growth, with Naturium brand up 74.3%. Edgewell (EPC) saw 3.0% sales growth, driven by Edge and Cremo shave products. Perrigo (PRGO) reported 9.3% year-over-year growth in private label infant formula sales.
BlackRock, Inc. disclosed a substantial acquisition of shares in Perrigo Company PLC on September 11, 2026, as per the Irish Takeover Panel's SAR 6 rules. The disclosure was made on September 14, 2026. BlackRock is the party making the disclosure, with no other persons acting in concert mentioned. The acquisition may impact Perrigo's shareholder structure and market position.
Perrigo (PRGO) reported weak Q2 2026 earnings with a 3.1% sales decline and 21% drop in core earnings. The company's gross and operating margins also fell. Despite paying a $0.29 dividend, risks include weak performance, asset sales, and leadership uncertainty following the abrupt departure of its CEO. Investors are advised to wait for a new CEO's plan before considering the stock.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PRGO (PERRIGO Co plc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PRGO coverage spans earnings, market movers and corporate actions.
Better-than‑category growth could spark short‑term buying.
BlackRock, Inc. disclosed a substantial acquisition of shares in Perrigo Company PLC on September 11, 2026, as per the Irish Takeover Panel's SAR 6 rules. The disclosure was made on September 14, 2026. BlackRock is the party making the disclosure, with no other persons acting in concert mentioned. The acquisition may impact Perrigo's shareholder structure and market position.
Earnings miss and leadership uncertainty likely pressure the stock lower.
Earnings-call details point to near-term margin pressure from volume and mix, partially offset by infant formula profitability and share gains.
Guidance maintenance plus portfolio actions and cost-savings targets frame a clearer path to margin support, with near-term demand normalization signals in U.S. OTC.
AlphAI scores every news story that mentions PRGO with an AI model for sentiment and relevance, and aggregates insider trades from PERRIGO Co plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Elf Beauty (ELF) shares rose after Canaccord's sales tracker showed 11.6% year-over-year dollar sales growth, with Naturium brand up 74.3%. Edgewell (EPC) saw 3.0% sales growth, driven by Edge and Cremo shave products. Perrigo (PRGO) reported 9.3% year-over-year growth in private label infant formula sales.
2 min readBlackRock, Inc. disclosed a substantial acquisition of shares in Perrigo Company PLC on September 11, 2026, as per the Irish Takeover Panel's SAR 6 rules. The disclosure was made on September 14, 2026. BlackRock is the party making the disclosure, with no other persons acting in concert mentioned. The acquisition may impact Perrigo's shareholder structure and market position.
1 min readPerrigo (PRGO) reported weak Q2 2026 earnings with a 3.1% sales decline and 21% drop in core earnings. The company's gross and operating margins also fell. Despite paying a $0.29 dividend, risks include weak performance, asset sales, and leadership uncertainty following the abrupt departure of its CEO. Investors are advised to wait for a new CEO's plan before considering the stock.
3 min readPerrigo (PRGO) reported weaker Q2 self-care and specialty-care demand in Europe and lower store-brand minoxidil and Mederma comparisons, while U.S. OTC volumes turned positive in late July. Infant formula revenue rose 23% YoY. Core adjusted gross margin fell 250 bps to 37%. Perrigo sold Dermacosmetics for $359M, using proceeds to reduce debt, and reiterated its 2026 outlook, including about -$0.60 EPS from under-absorption.
4 min readPerrigo (Q2 2026 earnings call) said core net sales fell 3.1% due to temporary seasonal softness and European retailer destocking, while it gained market share in U.S. store-brand OTC and key European brands. The company maintained full-year 2026 guidance, expects $80m-$100m savings by 2027, and noted a $359m Dermacosmetics divestiture and reviews of Infant Formula and Oral Care.
7 min readBiotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readInvesting.com reports Perrigo (PRGO) shares rose 24.4% to $13.41 after the company posted Q2 2026 results above analyst estimates. All-in adjusted diluted EPS was $0.50 versus $0.34 expected, and revenue was about $1.02B versus $1.01B. Perrigo cited cost savings and its Three-S strategy, reaffirmed 2026 EPS guidance, and said €305.6M from the Dermacosmetics sale will aid debt reduction.
4 min readPerrigo Co. plc (PRGO) reported Q2 profit despite lower sales. Net income was $74.5M versus a $8.4M loss a year earlier. EPS was $0.53 versus a loss of $0.06. Net sales fell to $1.02B from $1.06B. Perrigo reaffirmed FY2026 outlook, with adjusted EPS of $2.00 to $2.30. Shares rose about 11% premarket to $12.
2 min readPERRIGO Co plc (PRGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations • Execution of Three-S plan driving continued improvement in underlying business fundamentals, including market share growth in U.S. store-brand OTC and key European brands • Streamlined
6 min readPERRIGO Co plc (PRGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. prgo-20260629 0001585364 false 0001585364 2026-06-29 2026-06-29 0001585364 prgo:OrdinaryShares0001ParValueMember 2026-06-29 2026-06-29 0001585364 prgo:A4.900SeniorNoteDue2030Member 2026-06-29 2026-06-29 0001585364 prgo:A6.125SeniorNotesDue2032Member 2026-06-29 2026-06-29 00015853
2 min read
